celecoxib has been researched along with Experimental Mammary Neoplasms in 34 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The therapeutic benefits of combined MCT with cyclophosphamide plus celecoxib on mammary adenocarcinomas together with its very low toxicity profile warrant further study in an attempt to make the translation into the clinic." | 7.77 | Antitumoral and antimetastatic effects of metronomic chemotherapy with cyclophosphamide combined with celecoxib on murine mammary adenocarcinomas. ( Bonfil, RD; Mainetti, LE; Rossa, A; Rozados, VR; Scharovsky, OG, 2011) |
| "This study showed that in NMU-induced mammary cancer in rats, the combination of resveratrol and celecoxib led to a significant reduction in all tumor parameters." | 5.40 | Resveratrol enhances the chemopreventive effect of celecoxib in chemically induced breast cancer in rats. ( Bojková, B; Ekmekcioglu, C; Fedoročko, P; Jäger, W; Jendželovský, R; Kajo, K; Kassayová, M; Kisková, T; Kokošová, N; Kubatka, P; Maier-Salamon, A; Mikeš, J; Orendáš, P; Papčová, Z; Rentsen, E; Svoboda, M; Thalhammer, T, 2014) |
| "Celecoxib was administered i." | 5.31 | Chronotherapy and chronotoxicity of the cyclooxygenase-2 inhibitor, celecoxib, in athymic mice bearing human breast cancer xenografts. ( Blumenthal, RD; Burton, J; Flefleh, C; Goldenberg, DM; Lew, W; Waskewich, C, 2001) |
| "The therapeutic benefits of combined MCT with cyclophosphamide plus celecoxib on mammary adenocarcinomas together with its very low toxicity profile warrant further study in an attempt to make the translation into the clinic." | 3.77 | Antitumoral and antimetastatic effects of metronomic chemotherapy with cyclophosphamide combined with celecoxib on murine mammary adenocarcinomas. ( Bonfil, RD; Mainetti, LE; Rossa, A; Rozados, VR; Scharovsky, OG, 2011) |
| "Chronic inflammation has been directly linked to cancer progression." | 1.43 | Celecoxib and fish oil: a combination strategy for decreased inflammatory mediators in early stages of experimental mammary cancer. ( Agnihotri, N; Bhatnagar, A; Negi, AK, 2016) |
| "Celecoxib (100 µM) was found to induce downregulation of COX-2 protein expression." | 1.40 | Usefulness of selective COX-2 inhibitors as therapeutic agents against canine mammary tumors. ( Asano, R; Saito, T; Tamura, D, 2014) |
| " As long-term use of COX-2 inhibitors (COX-2i) can promote thrombo-embolic events, we tested an alternative target, prostaglandin E2 receptor EP4 subtype (EP4), downstream of COX-2." | 1.40 | Prostaglandin E2 receptor EP4 as the common target on cancer cells and macrophages to abolish angiogenesis, lymphangiogenesis, metastasis, and stem-like cell functions. ( Girish, GV; Lala, PK; Liu, L; Majumder, M; Xin, X, 2014) |
| "This study showed that in NMU-induced mammary cancer in rats, the combination of resveratrol and celecoxib led to a significant reduction in all tumor parameters." | 1.40 | Resveratrol enhances the chemopreventive effect of celecoxib in chemically induced breast cancer in rats. ( Bojková, B; Ekmekcioglu, C; Fedoročko, P; Jäger, W; Jendželovský, R; Kajo, K; Kassayová, M; Kisková, T; Kokošová, N; Kubatka, P; Maier-Salamon, A; Mikeš, J; Orendáš, P; Papčová, Z; Rentsen, E; Svoboda, M; Thalhammer, T, 2014) |
| "Celecoxib and anti-Gr1 treatment may be useful for blockade of these processes, thereby preventing brain metastasis in patients with breast cancer." | 1.39 | Premetastatic soil and prevention of breast cancer brain metastasis. ( Fellows-Mayle, W; Ikeura, M; Kohanbash, G; Kosaka, A; Liu, Y; Okada, H; Snyder, LA, 2013) |
| " Therefore, the present study was designed to investigate the effect of combined dosage of celecoxib and n-3 PUFA-rich fish oil in experimental mammary carcinogenesis." | 1.39 | Alteration in apoptosis and cell cycle by celecoxib and/or fish oil in 7,12-dimethyl benzene (α) anthracene-induced mammary carcinogenesis. ( Agnihotri, N; Bhatnagar, A; Kansal, S; Negi, AK, 2013) |
| "Pretreatment with celecoxib and fish oil in DMBA-treated animals led to normal histology, increase in DNA fragmentation, and decrease in TSA and LASA levels with reduced oxidative stress, and the effect was more pronounced than animals pretreated with either celecoxib/fish oil alone suggesting a synergistic effect of the two regimens." | 1.37 | Evaluation of the role of oxidative stress in chemopreventive action of fish oil and celecoxib in the initiation phase of 7,12-dimethyl benz(α)anthracene-induced mammary carcinogenesis. ( Aggarwal, R; Agnihotri, N; Kansal, S; Kaur, R; Negi, AK; Sarotra, P; Sharma, G, 2011) |
| "The sites of secondary metastasis and the associated inflammatory microenvironment were evaluated." | 1.37 | Collagen induced arthritis increases secondary metastasis in MMTV-PyV MT mouse model of mammary cancer. ( Ghosh, S; Gruber, HE; Mukherjee, P; Pathangey, LB; Roy, LD; Tinder, TL, 2011) |
| "Celecoxib was administered daily at a concentration of 1." | 1.35 | Celecoxib and melatonin in prevention of female rat mammary carcinogenesis. ( Ahlers, I; Ahlersova, E; Bojkova, B; Kajo, K; Kassayova, M; Kubatka, P; Orendas, P; Pec, M, 2009) |
| "Lung and bone metastasis and the associated inflammatory milieu were evaluated in the arthritic versus the non-arthritic mice." | 1.35 | Breast-cancer-associated metastasis is significantly increased in a model of autoimmune arthritis. ( Das Roy, L; Gruber, HE; Mukherjee, P; Pathangey, LB; Schettini, JL; Tinder, TL, 2009) |
| " This study was to evaluate the chemopreventive effect of tamoxifen combined with celecoxib, a COX-2 selective inhibitor, on 7,12-dimethylbenz anthracene (DMBA)-induced breast cancer in rats." | 1.33 | [Chemopreventive effect of tamoxifen combined with celecoxib on DMBA-induced breast cancer in rats]. ( Dai, ZJ; Kang, HF; Liu, XX; Wang, XJ; Xue, FJ; Xue, XH, 2006) |
| "Celecoxib-treated mice also developed fewer tumors (1." | 1.32 | The cyclooxygenase-2 inhibitor, celecoxib, prevents the development of mammary tumors in Her-2/neu mice. ( Daskalakis, C; Flynn, J; Gallatig, K; Lanza-Jacoby, S; Masferrer, JL; Miller, S; Russo, IH; Sembhi, H; Zweifel, BS, 2003) |
| "Celecoxib alone was most effective with a reduction in 98% of the metastases, yet distinctions were observed in the results with respect to the local recurrences, blood levels for the inhibitors and tissue production of prostaglandin E2." | 1.32 | Control of pulmonary metastases of rat mammary cancer by inhibition of uPA and COX-2, singly and in combination. ( Evans, DM; Sloan Stakleff, KD, 2004) |
| "Treatment with celecoxib (500 ppm) significantly reduced the incidence of mammary tumors in MMTV/neu mice (P = 0." | 1.31 | Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. ( Brown, AM; Dannenberg, AJ; Deora, A; Du, B; Howe, LR; Hudis, C; Masferrer, JL; Muller, WJ; Patel, J; Subbaramaiah, K; Thaler, HT, 2002) |
| "celecoxib-treated group, and 1500 p." | 1.31 | Chemopreventive effect of celecoxib and expression of cyclooxygenase-1 and cyclooxygenase-2 on chemically-induced rat mammary tumours. ( Jang, TJ; Jung, HG; Jung, KH; O, MK, 2002) |
| "Celecoxib was administered i." | 1.31 | Chronotherapy and chronotoxicity of the cyclooxygenase-2 inhibitor, celecoxib, in athymic mice bearing human breast cancer xenografts. ( Blumenthal, RD; Burton, J; Flefleh, C; Goldenberg, DM; Lew, W; Waskewich, C, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 22 (64.71) | 29.6817 |
| 2010's | 12 (35.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, Y | 2 |
| Kosaka, A | 1 |
| Ikeura, M | 1 |
| Kohanbash, G | 1 |
| Fellows-Mayle, W | 1 |
| Snyder, LA | 1 |
| Okada, H | 1 |
| Negi, AK | 4 |
| Kansal, S | 2 |
| Bhatnagar, A | 3 |
| Agnihotri, N | 4 |
| Saito, T | 1 |
| Tamura, D | 1 |
| Asano, R | 1 |
| Majumder, M | 1 |
| Xin, X | 1 |
| Liu, L | 2 |
| Girish, GV | 1 |
| Lala, PK | 1 |
| Kisková, T | 1 |
| Jendželovský, R | 1 |
| Rentsen, E | 1 |
| Maier-Salamon, A | 1 |
| Kokošová, N | 1 |
| Papčová, Z | 1 |
| Mikeš, J | 1 |
| Orendáš, P | 2 |
| Bojková, B | 2 |
| Kubatka, P | 2 |
| Svoboda, M | 1 |
| Kajo, K | 2 |
| Fedoročko, P | 1 |
| Jäger, W | 1 |
| Ekmekcioglu, C | 1 |
| Kassayová, M | 2 |
| Thalhammer, T | 1 |
| Booth, L | 1 |
| Roberts, JL | 1 |
| Cruickshanks, N | 1 |
| Tavallai, S | 1 |
| Webb, T | 1 |
| Samuel, P | 1 |
| Conley, A | 1 |
| Binion, B | 1 |
| Young, HF | 1 |
| Poklepovic, A | 1 |
| Spiegel, S | 1 |
| Dent, P | 1 |
| Brown, PH | 3 |
| Subbaramaiah, K | 2 |
| Salmon, AP | 1 |
| Baker, R | 1 |
| Newman, RA | 1 |
| Yang, P | 1 |
| Zhou, XK | 1 |
| Bissonnette, RP | 2 |
| Dannenberg, AJ | 2 |
| Howe, LR | 2 |
| Medina, D | 2 |
| Kittrell, F | 1 |
| Hill, J | 2 |
| Zhang, Y | 1 |
| Hilsenbeck, SG | 1 |
| Bissonette, R | 1 |
| Abba, MC | 1 |
| Hu, Y | 1 |
| Levy, CC | 1 |
| Gaddis, S | 1 |
| Kittrell, FS | 1 |
| Aldaz, CM | 1 |
| Woditschka, S | 1 |
| Haag, JD | 1 |
| Sullivan, R | 1 |
| Gould, MN | 1 |
| Ahlers, I | 1 |
| Pec, M | 1 |
| Ahlersova, E | 1 |
| Das Roy, L | 1 |
| Pathangey, LB | 2 |
| Tinder, TL | 2 |
| Schettini, JL | 1 |
| Gruber, HE | 2 |
| Mukherjee, P | 2 |
| Mainetti, LE | 1 |
| Rozados, VR | 1 |
| Rossa, A | 1 |
| Bonfil, RD | 1 |
| Scharovsky, OG | 1 |
| Kaur, R | 1 |
| Sarotra, P | 1 |
| Sharma, G | 1 |
| Aggarwal, R | 1 |
| Roy, LD | 1 |
| Ghosh, S | 1 |
| Zhang, B | 1 |
| Ma, X | 2 |
| Li, Z | 1 |
| Gao, X | 1 |
| Wang, F | 1 |
| Shen, G | 1 |
| Sang, Y | 1 |
| Li, M | 1 |
| Li, Y | 1 |
| Zhao, J | 1 |
| Wei, Y | 1 |
| Patel, J | 1 |
| Masferrer, JL | 2 |
| Deora, A | 1 |
| Hudis, C | 1 |
| Thaler, HT | 1 |
| Muller, WJ | 1 |
| Du, B | 1 |
| Brown, AM | 1 |
| Jang, TJ | 1 |
| Jung, HG | 1 |
| Jung, KH | 1 |
| O, MK | 1 |
| Lanza-Jacoby, S | 1 |
| Miller, S | 1 |
| Flynn, J | 1 |
| Gallatig, K | 1 |
| Daskalakis, C | 1 |
| Zweifel, BS | 1 |
| Sembhi, H | 1 |
| Russo, IH | 1 |
| Badawi, AF | 2 |
| Eldeen, MB | 1 |
| Ross, EA | 1 |
| Badr, MZ | 1 |
| Awara, WM | 1 |
| El-Sisi, AE | 1 |
| El-Sayad, ME | 1 |
| Goda, AE | 1 |
| Evans, DM | 1 |
| Sloan Stakleff, KD | 1 |
| Kundu, N | 1 |
| Walser, TC | 1 |
| Fulton, AM | 1 |
| Narko, K | 1 |
| Zweifel, B | 1 |
| Trifan, O | 1 |
| Ristimäki, A | 1 |
| Lane, TF | 1 |
| Hla, T | 1 |
| Ferrario, A | 1 |
| Fisher, AM | 1 |
| Rucker, N | 1 |
| Gomer, CJ | 1 |
| Fenton, BM | 2 |
| Paoni, SF | 2 |
| Grimwood, B | 1 |
| Ding, I | 2 |
| Kang, HF | 2 |
| Wang, XJ | 2 |
| Liu, XX | 2 |
| Dai, ZJ | 2 |
| Xue, FJ | 2 |
| Xue, XH | 2 |
| Beauchamp, BK | 1 |
| Okunieff, P | 1 |
| Blumenthal, RD | 1 |
| Waskewich, C | 1 |
| Goldenberg, DM | 1 |
| Lew, W | 1 |
| Flefleh, C | 1 |
| Burton, J | 1 |
| Medhurst, SJ | 1 |
| Walker, K | 1 |
| Bowes, M | 1 |
| Kidd, BL | 1 |
| Glatt, M | 1 |
| Muller, M | 1 |
| Hattenberger, M | 1 |
| Vaxelaire, J | 1 |
| O'Reilly, T | 1 |
| Wotherspoon, G | 1 |
| Winter, J | 1 |
| Green, J | 1 |
| Urban, L | 1 |
| Lu, S | 1 |
| Zhang, X | 1 |
| El-Sohemy, A | 1 |
| Archer, MC | 1 |
34 other studies available for celecoxib and Experimental Mammary Neoplasms
| Article | Year |
|---|---|
Premetastatic soil and prevention of breast cancer brain metastasis.
Topics: Adenocarcinoma; Animals; Apoptosis; Blotting, Western; Brain Neoplasms; Calgranulin B; CD11b Antigen | 2013 |
Alteration in apoptosis and cell cycle by celecoxib and/or fish oil in 7,12-dimethyl benzene (α) anthracene-induced mammary carcinogenesis.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis | 2013 |
Usefulness of selective COX-2 inhibitors as therapeutic agents against canine mammary tumors.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Celecoxib; Cell Line, Tumor; Cell Prol | 2014 |
Prostaglandin E2 receptor EP4 as the common target on cancer cells and macrophages to abolish angiogenesis, lymphangiogenesis, metastasis, and stem-like cell functions.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Benzamides; Celecoxib; Cell Line, Tumor; | 2014 |
Resveratrol enhances the chemopreventive effect of celecoxib in chemically induced breast cancer in rats.
Topics: Animals; Anticarcinogenic Agents; Breast Neoplasms; Carcinogens; Celecoxib; Chemoprevention; Drug Sy | 2014 |
PDE5 inhibitors enhance celecoxib killing in multiple tumor types.
Topics: Animals; Apoptosis; Autophagy; Celecoxib; Cell Line, Tumor; Drug Synergism; Endoplasmic Reticulum St | 2015 |
Celecoxib and fish oil: a combination strategy for decreased inflammatory mediators in early stages of experimental mammary cancer.
Topics: Animals; Anti-Inflammatory Agents; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cytokin | 2016 |
Fish oil augments celecoxib mediated alteration in apoptotic pathway in the initiation phase of 7,12-dimethylbenz(α)anthracene-induced mammary carcinogenesis.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Apoptosis; bcl-2-Associated X Protein; Carcinogenesis; Ca | 2016 |
Combination chemoprevention of HER2/neu-induced breast cancer using a cyclooxygenase-2 inhibitor and a retinoid X receptor-selective retinoid.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Carcinoma; Celecoxib; Cell Tran | 2008 |
Prevention of tumorigenesis in p53-null mammary epithelium by rexinoid bexarotene, tyrosine kinase inhibitor gefitinib, and celecoxib.
Topics: Animals; Anticarcinogenic Agents; Bexarotene; Celecoxib; Cyclooxygenase Inhibitors; Disease Models, | 2009 |
Identification of modulated genes by three classes of chemopreventive agents at preneoplastic stages in a p53-null mouse mammary tumor model.
Topics: Animals; Anticarcinogenic Agents; Bexarotene; Biomarkers, Tumor; Celecoxib; Cyclooxygenase Inhibitor | 2009 |
A short-term rat mammary carcinogenesis model for the prevention of hormonally responsive and nonresponsive in situ carcinomas.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents, Hormonal; Apoptosis; Bexarotene; Carcinoma | 2009 |
Celecoxib and melatonin in prevention of female rat mammary carcinogenesis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Celecoxib; Drug Therapy, | 2009 |
Breast-cancer-associated metastasis is significantly increased in a model of autoimmune arthritis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Arthritis; Autoimmune Dise | 2009 |
Antitumoral and antimetastatic effects of metronomic chemotherapy with cyclophosphamide combined with celecoxib on murine mammary adenocarcinomas.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Cyclophosphamide | 2011 |
Evaluation of the role of oxidative stress in chemopreventive action of fish oil and celecoxib in the initiation phase of 7,12-dimethyl benz(α)anthracene-induced mammary carcinogenesis.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Carcinogens; Celecoxib; Cyclooxygenase 2; Cyclooxygenase | 2011 |
Collagen induced arthritis increases secondary metastasis in MMTV-PyV MT mouse model of mammary cancer.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Bone Neoplasms; Celecoxib; Collagen Type | 2011 |
Celecoxib enhances the efficacy of 15-hydroxyprostaglandin dehydrogenase gene therapy in treating murine breast cancer.
Topics: Animals; Apoptosis; Celecoxib; Cell Line, Tumor; Combined Modality Therapy; Cyclooxygenase 2; Cycloo | 2013 |
Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer.
Topics: Animals; Anticarcinogenic Agents; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxy | 2002 |
Chemopreventive effect of celecoxib and expression of cyclooxygenase-1 and cyclooxygenase-2 on chemically-induced rat mammary tumours.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antineoplastic Agents; Blotting, Western; Celecoxib; Cycl | 2002 |
The cyclooxygenase-2 inhibitor, celecoxib, prevents the development of mammary tumors in Her-2/neu mice.
Topics: Animals; Biopsy, Needle; Blotting, Western; Celecoxib; Cyclooxygenase Inhibitors; Disease Models, An | 2003 |
Inhibition of rat mammary gland carcinogenesis by simultaneous targeting of cyclooxygenase-2 and peroxisome proliferator-activated receptor gamma.
Topics: Animals; Anticarcinogenic Agents; Apoptosis; Carcinogens; Celecoxib; Cell Cycle; Cell Division; Cycl | 2004 |
The potential role of cyclooxygenase-2 inhibitors in the treatment of experimentally-induced mammary tumour: does celecoxib enhance the anti-tumour activity of doxorubicin?
Topics: Animals; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Doxoru | 2004 |
Control of pulmonary metastases of rat mammary cancer by inhibition of uPA and COX-2, singly and in combination.
Topics: Amiloride; Animals; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibit | 2004 |
Cyclooxygenase inhibitors modulate NK activities that control metastatic disease.
Topics: Animals; Celecoxib; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase | 2005 |
COX-2 inhibitors and genetic background reduce mammary tumorigenesis in cyclooxygenase-2 transgenic mice.
Topics: Animals; Base Sequence; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inh | 2005 |
Celecoxib and NS-398 enhance photodynamic therapy by increasing in vitro apoptosis and decreasing in vivo inflammatory and angiogenic factors.
Topics: Animals; Apoptosis; Celecoxib; Cyclooxygenase Inhibitors; Dihematoporphyrin Ether; Dinoprostone; Dru | 2005 |
Varied response of spontaneous tumors to antiangiogenic agents.
Topics: Angiogenesis Inhibitors; Animals; Celecoxib; Endostatins; Female; Hypoxia; Mammary Neoplasms, Experi | 2005 |
[Chemopreventive effect of tamoxifen combined with celecoxib on DMBA-induced breast cancer in rats].
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antineoplastic Combined Chemotherapy Protocols; Celecoxib | 2006 |
[Chemopreventive effect of celecoxib against DMBA-induced breast cancer and its mechanism].
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Celecoxib; Cyclooxygenase 2; Cyclooxygenase Inhibitors; D | 2006 |
Characterization of the effects of antiangiogenic agents on tumor pathophysiology.
Topics: Angiogenesis Inhibitors; Animals; Celecoxib; Cell Hypoxia; Cyclooxygenase 2; Cyclooxygenase 2 Inhibi | 2001 |
Chronotherapy and chronotoxicity of the cyclooxygenase-2 inhibitor, celecoxib, in athymic mice bearing human breast cancer xenografts.
Topics: Animals; Antineoplastic Agents; Aspartate Aminotransferases; Bilirubin; Blood Urea Nitrogen; Blottin | 2001 |
A rat model of bone cancer pain.
Topics: Analgesics, Opioid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Behavior, Animal; Body Tempera | 2002 |
Cyclooxygenase-2 inhibitor celecoxib inhibits promotion of mammary tumorigenesis in rats fed a high fat diet rich in n-6 polyunsaturated fatty acids.
Topics: Animals; Anticarcinogenic Agents; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxy | 2002 |